You are here

Asia

BMS buys Asian rights to key growth drug Camzyos

BMS buys Asian rights to key growth drug Camzyos

Pharmaphorum

Bristol Myers Squibb

obstructive hypertrophic cardiomyopathy

Flag link:

Eisai files Leqembi in Korea, as US prospects firm up

Eisai files Leqembi in Korea, as US prospects firm up

Pharmaphorum

Alzheimer's disease

Flag link:

Astellas' menopause therapy accepted for FDA review 5 months after late-phase study mars record

Astellas' menopause therapy accepted for FDA review 5 months after late-phase study mars record

Fierce Biotech

clinical trials

Flag link:

Merck KGaA launches Asia startup scheme to locate next generation of partnerships

Merck KGaA launches Asia startup scheme to locate next generation of partnerships

Fierce Biotech

Flag link:

Small RSV contender eyes 'first-to-market' opportunity with $225M Asia deal

Small RSV contender eyes 'first-to-market' opportunity with $225M Asia deal

Endpoints

Bavarian Nordic

Flag link:

Kiniksa inks licensing deal to take a Regeneron castoff into Asian markets

Kiniksa inks licensing deal to take a Regeneron castoff into Asian markets

Endpoints

Kiniksa Pharmaceuticals

Huadong Medicine

Flag link:

Covid-19 vaccine maker Moderna to set up subsidiary in Singapore as it boosts regional presence

Covid-19 vaccine maker Moderna to set up subsidiary in Singapore as it boosts regional presence

Today Online, Singapore

Moderna Therapeutics

Flag link:

2 Medtech Giants Are Working to Enhance Cardiac Care in Southeast Asia

2 Medtech Giants Are Working to Enhance Cardiac Care in Southeast Asia

Medical Devices and Diagnostics Industry

Boston Scientific

interventional cardiology

Flag link:

Prestige BioPharma and Dr. Reddy’s partner to sell trastuzumab biosimilar

Prestige BioPharma and Dr. Reddy’s partner to sell trastuzumab biosimilar

Pharmaceutical Business Review

Prestige BioPharma

Flag link:

Is Vaccine Latecomer Inovio Making a Comeback?

Is Vaccine Latecomer Inovio Making a Comeback?

Motley Fool

clinical trials

Flag link:

Landos Biopharma teams up with LianBio for $218M-plus collab and sales deal for 2 immunology assets in Asia

Landos Biopharma teams up with LianBio for $218M-plus collab and sales deal for 2 immunology assets in Asia

Fierce Biotech

Landos Biopharma

ulcerative colitis

Crohn's Disease

Flag link:

Samsung Biologics and AstraZeneca launch strategic manufacturing partnership

Samsung Biologics and AstraZeneca launch strategic manufacturing partnership

Biopharma Reporter

Samsung BioLogics

drug manufacturing

Flag link:

Amgen Is Making 3 Big Bets -- Will They Pay Off for Investors?

Amgen Is Making 3 Big Bets -- Will They Pay Off for Investors?

Motley Fool

Flag link:

With Immunomedics ADC deal, Everest bolsters cancer pipeline

With Immunomedics ADC deal, Everest bolsters cancer pipeline

BioCentury

sacituzumab govitecan

Everest Medicines

Flag link:

Ascletis Pharma, Asia’s first pre-profit listed biotech, plunges in Hong Kong three days after debut

Ascletis Pharma, Asia’s first pre-profit listed biotech, plunges in Hong Kong three days after debut

South China Morning Post

Flag link:

Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories

Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories

CP Wire

Arcus Biosciences

Taiho Pharmaceutical

Flag link:

With the ink on their $25M Astellas deal still drying, Aquinox shares get blasted on PhIII failure

With the ink on their $25M Astellas deal still drying, Aquinox shares get blasted on PhIII failure

Endpoints

Aquinox Pharmaceuticals

clinical trials

Interstitial Cystitis

Flag link:

On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression

On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression

Endpoints

SAGE Therapeutics

Flag link:

Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie

Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie

Endpoints

Flag link:

Astellas to pay Aquinox $25M upfront for regional rights to phase 3 inflammatory pain drug

Astellas to pay Aquinox $25M upfront for regional rights to phase 3 inflammatory pain drug

Fierce Biotech

Aquinox Pharmaceuticals

SHIP1 activator

Flag link:

Pages